Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Thursday, April 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Emergent BioSolutions Inc. will hold a conference call on April 30, 2026, to discuss its financial results for the first quarter of 2026. Participants can join via webcast or telephone after registering. A replay will be available on the company's Investors page. Emergent continues to focus on public health solutions.
Price reaction · baseline $8.66 (2026-04-15 close) · hit after-hours · 2 other EBS headline(s) in the window, move may be shared
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Emergent BioSolutions is actively engaging with investors.
  • The company is committed to transparency by hosting a conference call.
  • They have a long-standing mission to protect public health.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026.
Participants can access the conference call live viawebcastand also by visiting theInvestorspage of Emergent’s website. To participate via telephone, please register in advance at thislink. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from theInvestorspage of Emergent’s website.
About Emergent BioSolutionsAt Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit ourwebsiteand follow us onLinkedIn,X,Instagram,Apple PodcastsandSpotify.

Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com

Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com

Frequently Asked Questions

When will Emergent BioSolutions report Q1 2026 results?

Emergent BioSolutions will report its Q1 2026 financial results on April 30, 2026.

How can I participate in the conference call?

Participants can join the conference call via webcast or telephone after registering in advance.

Where can I find the replay of the call?

A replay of the conference call will be available on the Investors page of Emergent's website.

What is Emergent BioSolutions' mission?

Emergent BioSolutions aims to protect and save lives by providing health solutions.

ShareAdd on Google
Tags: EBS Viatris Investor Conferences Healthcare Emergent BioSolutions financial results conference call public health
Last updated: Apr 16, 2026

Biotech snapshot

Cash runway
$141M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FLU-IGIVPhase 2
Influenza A H3N2 →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →